Zantac NDMA cancer lawsuit: where MDL 2924 actually stands after the Daubert dismissals

The Zantac litigation is one of the most procedurally complex active mass torts in the United States, with the federal multidistrict litigation effectively dismissed, the majority of state court cases settled by the largest defendant, and the remaining cases proceeding on multiple state court tracks with varying outcomes. The case theory alleges that ranitidine, the active ingredient in Zantac and various generic heartburn medications, is an inherently unstable molecule that breaks down into N-Nitrosodimethylamine (NDMA), a chemical the Environmental Protection Agency classifies as a probable human carcinogen. The breakdown is accelerated by exposure to heat and time, which means ranitidine products sitting on warehouse shelves or in consumer medicine cabinets could accumulate NDMA at levels far above safe exposure thresholds.

MDL 2924 (In re: Zantac (Ranitidine) Products Liability Litigation), centralized in the U.S. District Court for the Southern District of Florida before Judge Robin L. Rosenberg, was established in February 2020 after the FDA requested manufacturers withdraw all ranitidine products from the U.S. market. At its peak the MDL had more than 50,000 pending claims plus tens of thousands more in state court tracks. On December 6, 2022, Judge Rosenberg issued a 341-page opinion granting summary judgment for the defendants, finding that the plaintiffs' general causation experts used methodology that didn't satisfy the Daubert standard for admissibility. The exclusion effectively dismissed the federal MDL.

The state court litigation tracks have produced mixed outcomes. In October 2024, GlaxoSmithKline (GSK) announced settlements covering approximately 80,000 cases (93% of state court inventory) for up to $2.2 billion. Sanofi and Pfizer offered approximately $350 million to settle 14,000+ additional cases. Boehringer Ingelheim has remained more aggressive in defending cases and won a defense verdict in Cook County Circuit Court in November 2025. In April 2026, Delaware Superior Court Judge Francis J. Jones dismissed approximately 80,000 Delaware state court cases based on Daubert exclusion of plaintiff experts, applying the rulings retroactively to all filed and future cases. The federal MDL appeal remains pending in the 11th Circuit.

This is the science behind the NDMA-cancer theory, the procedural history that has produced the current fragmented state of the litigation, what's still available for filing-eligible claimants, and the strategic considerations for those navigating the remaining cases.

The science: ranitidine and NDMA

Ranitidine was developed by Glaxo in the 1970s and approved by the FDA in 1983. The drug was marketed as Zantac and quickly became one of the best-selling prescription medications in the United States, used by tens of millions of consumers for acid reflux, heartburn, and related gastrointestinal conditions. Over-the-counter versions became available in the 1990s, expanding consumer access.

The cancer concerns emerged in 2019 when independent pharmacy laboratory Valisure tested various ranitidine products and found extremely high NDMA levels, in some cases more than 26,000 nanograms per tablet (compared to the FDA's daily limit of 96 nanograms). Valisure filed a citizen petition with the FDA in September 2019 requesting recall of all ranitidine products.

The chemical mechanism:

Ranitidine contains an N-nitroso amine functional group that is inherently unstable. Under normal storage conditions over time, particularly with exposure to heat, the molecule can self-degrade into NDMA. The longer ranitidine sits and the warmer it gets, the more NDMA accumulates.

NDMA has been classified by multiple authorities as a probable human carcinogen. The International Agency for Research on Cancer (IARC) and the U.S. EPA both list NDMA as a Group 2A carcinogen (probably carcinogenic to humans). The chemical specifically targets cells with rapid turnover, with particularly strong associations to cancers of the digestive system and urinary tract.

The FDA's investigation confirmed that NDMA in ranitidine products increased over time and could reach levels associated with elevated cancer risk. In April 2020, the FDA requested all manufacturers withdraw ranitidine products from the U.S. market. The withdrawal was effectively the largest pharmaceutical product recall in recent history.

The cancers alleged to be caused by NDMA exposure from ranitidine include:

Bladder cancer (the most common cancer claim, based on NDMA's specific targeting of urinary tract tissues).

Stomach cancer.

Liver cancer.

Esophageal cancer.

Pancreatic cancer.

Colorectal cancer.

Other digestive system cancers in some cases.

The plaintiffs' theory: manufacturers knew or should have known of ranitidine's instability and NDMA generation problem from internal testing dating back to the 1980s, but continued selling the product without warning consumers of the cancer risk. The discovery in the litigation produced internal corporate documents suggesting the manufacturers were aware of stability and NDMA concerns long before the public disclosure.

The MDL dismissal and Daubert analysis

The federal MDL dismissal on December 6, 2022 was a watershed moment in the litigation. Judge Rosenberg's 341-page opinion found:

The plaintiffs' general causation experts used unreliable methodology to link ranitidine exposure to the cancers at issue.

The experts didn't adequately address dose-response relationships at the exposure levels actual consumers experienced.

The experts relied on extrapolation from animal studies and from much higher NDMA exposures than typical consumer use would produce.

The methodology didn't satisfy the Federal Rule of Evidence 702 reliability requirements as interpreted through the Daubert framework.

The exclusion of plaintiffs' general causation experts left the cases without admissible scientific evidence connecting ranitidine to the alleged cancers. Without general causation, individual cases couldn't proceed because the plaintiffs couldn't prove that ranitidine can cause the cancers in human populations generally, much less that it caused the cancers in specific plaintiffs.

The federal appeal of the MDL dismissal is pending in the U.S. Court of Appeals for the 11th Circuit. The appeal argues that Judge Rosenberg overstepped the gatekeeping role under Daubert by deciding the underlying scientific question rather than evaluating expert qualifications and methodology. The appellate decision is expected in 2026 or 2027 and could substantially affect the federal litigation if reversed.

State court tracks

After the federal MDL dismissal, the litigation continued in state courts under various tracks:

Delaware Superior Court became the largest state court track because Delaware has consent-by-registration jurisdiction allowing claims to be filed against pharmaceutical companies that have registered to do business in Delaware. Approximately 80,000 cases were pending in Delaware state court at the peak. The Delaware Supreme Court reversed initial trial court rulings that had allowed plaintiffs' experts to testify, directing stricter Daubert review. In April 2026, Delaware Superior Court Judge Francis J. Jones applied the stricter Daubert review and dismissed approximately 80,000 Delaware cases.

California Judicial Council Coordinated Proceedings (JCCP) (RANITIDINE PRODUCT CASES, JCCP No. 5150) consolidated California state court cases. The California framework operated alongside federal MDL with its own bellwether trial track and procedural framework.

Illinois state court cases included Cook County Circuit Court litigation. In November 2025, Boehringer Ingelheim won a defense verdict in Cook County, the first jury verdict in the litigation.

Connecticut state court cases are scheduled for bellwether trials beginning March 14, 2028 against main manufacturer Boehringer Ingelheim Pharmaceuticals. The Connecticut bellwether track is now the primary remaining trial framework for non-settled cases.

Other state courts including Pennsylvania, New Jersey, and various others have smaller dockets of pending cases.

The state court tracks have produced inconsistent outcomes. Some state courts have allowed plaintiff experts to testify and have permitted cases to proceed toward trial. Other state courts have followed the federal MDL's Daubert exclusion analysis and dismissed cases. The legal split is what has kept the broader litigation alive even after the federal MDL dismissal.

The settlement landscape

The settlement activity has been substantial but uneven across defendants:

GlaxoSmithKline (GSK) announced in October 2024 that it had reached settlement agreements covering approximately 80,000 Zantac lawsuits, accounting for roughly 93% of state court inventory at the time. The settlement value was reported at up to $2.2 billion. The agreements were negotiated with 10 major plaintiffs' law firms and were required to be fully implemented by mid-2025. The GSK settlement removed the most-named defendant from most of the litigation.

Sanofi and Pfizer offered approximately $350 million to settle 14,000+ additional cases. The settlements were smaller in scope than the GSK settlement but covered substantial additional case inventory.

Boehringer Ingelheim has remained more aggressive in defending cases and has not entered comparable global settlement agreements. Boehringer's defense strategy has included winning the November 2025 Cook County defense verdict and continuing to contest cases in remaining state court tracks.

Chattem Inc. and various other defendants have entered case-specific settlements in selected cases without global settlement frameworks.

The settlement amounts per case have varied based on cancer type, exposure history, severity, and other factors. The GSK settlement reportedly averaged $27,500 per case (calculated from $2.2 billion across 80,000 cases), though specific case values varied based on case-specific factors. Severe cases involving fatal cancers, prolonged exposure, and strong causation evidence reportedly received substantially higher amounts.

What's still available for filers

The procedural posture for new claims in 2026 is complicated:

Federal MDL. Effectively closed. The federal MDL was dismissed on Daubert grounds and remains pending appeal. New filings in federal court face the same Daubert exclusion that defeated the original cases.

Most state court tracks. Significantly narrowed. The Delaware track has been substantially eliminated by the April 2026 Daubert dismissal. Other state courts have varied responses to Daubert analysis.

Connecticut state court. Active. Bellwether trials scheduled for March 2028 against Boehringer Ingelheim. Plaintiffs with cases meeting Connecticut court requirements may still be filing-eligible.

Cases against Boehringer Ingelheim and other non-settled defendants. Available in some jurisdictions. Boehringer has remained the most-aggressive remaining defendant for new cases.

Cases involving generic ranitidine manufacturers. Some smaller generic manufacturers have settled or face continuing claims. The state-by-state analysis is fact-specific.

Eligibility requirements that plaintiffs' counsel typically apply:

Documented ranitidine use. The claimant used Zantac or generic ranitidine on a regular basis (typically daily or near-daily) for at least 6 months. Prescription records, pharmacy records, or contemporaneous documentation of over-the-counter use.

Diagnosed qualifying cancer. The claimant was diagnosed with one of the cancers alleged to be caused by NDMA exposure (bladder, stomach, liver, esophageal, pancreatic, colorectal, or other specified cancers). The diagnosis must be supported by medical records.

Temporal proximity. The cancer was diagnosed within a window of time after substantial ranitidine exposure that's consistent with the cancer's typical latency period. Very recent diagnoses with long-ago exposure are more challenging than cases with closer temporal proximity.

No significant alternative causation. Cases involving strong alternative cancer causes (heavy smoking with lung-adjacent cancers, occupational chemical exposure, etc.) face more difficult causation analysis.

Statute of limitations. Most cancer cases must be filed within 1-4 years of diagnosis depending on state. The discovery rule extends limitations when the plaintiff didn't know or should not have known of the ranitidine connection earlier.

The state-by-state procedural analysis is complex enough that most plaintiffs' counsel decline cases that don't have clearly viable jurisdictional paths.

How Zantac compares to other mass torts

The Zantac litigation represents an unusual pattern compared to other active mass torts:

Compared to Tylenol autism MDL 3043 where the federal MDL was also dismissed on Daubert grounds: Tylenol autism cases remain in similar procedural limbo pending federal appellate review. Both litigations show how Daubert exclusions can effectively end mass tort litigation despite substantial case volume.

Compared to Roundup litigation where the science survived Daubert challenge: Roundup cases proceeded to trials and produced substantial plaintiff verdicts and settlements. The contrast highlights how the scientific causation question determines mass tort outcomes more than case volume or apparent harm.

Compared to 3M Combat Arms which reached a global settlement: 3M had clear product defect evidence and strong bellwether plaintiff verdicts that drove the $6 billion settlement. Zantac never produced a comparable bellwether plaintiff verdict that would have driven settlement leverage.

Compared to Talcum powder litigation with similar product liability theory: Talc cases had stronger scientific support and produced significant plaintiff verdicts that drove substantial settlement activity. Zantac's weaker scientific support contributed to the different outcome.

The broader procedural framework for mass tort settlements is covered in our overview of how mass tort litigation works. Zantac illustrates the importance of expert admissibility in mass tort outcomes; cases that lose Daubert challenges can essentially fail regardless of underlying harm to plaintiffs.

Strategic considerations for current and prospective plaintiffs

For consumers with potential Zantac claims:

Don't expect federal MDL recovery. The federal MDL is dismissed and remains pending appeal. New federal filings face essentially the same outcome unless the 11th Circuit reverses Judge Rosenberg's Daubert ruling, which is unlikely.

Consult with mass tort attorneys experienced with Zantac-specific litigation. The procedural complexity (federal MDL dismissed, Delaware track substantially eliminated, GSK settlement covering most cases, ongoing Connecticut track, varying state court outcomes) requires specialized knowledge. Most general personal injury attorneys aren't equipped to handle the procedural complexity.

Identify whether you're potentially in the GSK settlement framework. Plaintiffs who had cases against GSK may have been included in the October 2024 settlement. Verifying whether your specific case was included is the first step in understanding what's still available.

For non-GSK cases. Cases primarily targeting Boehringer Ingelheim, Sanofi, Pfizer, or other defendants may have separate procedural posture. The analysis is defendant-specific.

Documentation requirements are demanding. Successful Zantac cases require substantial documentation: prescription/pharmacy records of ranitidine use, medical records establishing cancer diagnosis, evidence of regular use for sufficient duration, and no significant alternative causation. Cases with thin documentation are difficult to pursue successfully.

Be realistic about expected outcomes. Even cases that proceed to trial face the same general causation challenges that defeated the federal MDL. The November 2025 Cook County defense verdict illustrates that defense outcomes remain very possible. Settlement amounts in cases that resolve typically reflect the procedural risks involved.

Statute of limitations is critical. Cases must be filed within applicable limitations periods. The discovery rule provides some flexibility but has limits. Cases involving cancers diagnosed years ago with limitations periods that have run face dismissal regardless of merit.

For plaintiffs with cases in the GSK settlement framework, the procedural path runs through the settlement administrator. Settlement implementation was scheduled for completion by mid-2025; cases that should have been included but weren't may need separate analysis with counsel.

For plaintiffs with cases in Connecticut or other still-active state court tracks, the procedural path runs through the relevant state court framework. Connecticut bellwether trials in 2028 will substantially affect the trajectory of remaining cases.

The Zantac litigation illustrates how mass tort outcomes depend on the intersection of substantive case theory (here, the NDMA-cancer connection), expert admissibility under Daubert standards, and procedural strategy across federal and state court tracks. For cases where all three elements align, substantial recovery has been achieved (the GSK settlement). For cases where Daubert challenges succeed, the procedural framework can produce dismissals despite real harm to plaintiffs. The work for consumers considering filing in 2026 is identifying whether the remaining procedural paths are viable for their specific circumstances and engaging experienced counsel who understands the multi-track framework that the litigation has become.